NASDAQ$TELA
TELA Bio Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
TELA Bio reported strong revenue growth in the third quarter of 2021, driven by increased demand for OviTex products and expansion of the commercial organization, despite market volatility due to COVID-19.
TELA Bio reported a 44% increase in revenue for the third quarter of 2021 compared to the prior year, driven by expansion of the commercial organization, increased penetration within existing customer accounts and stronger than anticipated international sales. Revenue was $7.7 million. The company is maintaining its expectation for revenue to be in the range of $28.0 million to $30.0 million for the full year 2021.
- Revenue for the third quarter of 2021 was $7.7 million, a 44% increase compared to the prior year period.
- Gross profit for the third quarter of 2021 was $4.6 million, or 60% of revenue.
- Operating expenses were $11.8 million in the third quarter of 2021, compared to $10.2 million in the same period in 2020.
- Cash and Cash Equivalents at September 30, 2021 were $53.6 million.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$7.65M
Forward guidance
TELA Bio is maintaining its expectation for revenue to be in the range of $28.0 million to $30.0 million for the full year 2021, representing growth of 54% to 65% over the prior year period.
Headwinds
- Continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact this projection.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.5%
Avg return
Earnings day
-3.7%
Avg return
5 days after
+3.7%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -18.6% | — | |
| Q4 2025 | +1.7% | -25.8% | -12.0% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro